{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104958",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104958",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for pantoprazole and CYP2C19",
  "relatedDrugs" : [ {
    "objCls" : "Drug",
    "@id" : "https://www.pharmgkb.org/data/drug/PA450774",
    "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
    "id" : "PA450774",
    "name" : "pantoprazole"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA124",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA124",
    "symbol" : "CYP2C19",
    "name" : "cytochrome P450, family 2, subfamily C, polypeptide 19"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>For CYP2C19 ultrarapid metabolizers, be extra alert to insufficient response and consider increasing pantoprazole dose by 400%.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for pantoprazole based on <em>CYP2C19</em> genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  For the <em>CYP2C19</em> UM phenotype, they conclude to be extra alert to insufficient response and recommend to consider dose increase by 400%.</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Phenotype (Genotype) </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> <em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3) </td><td> None </td><td> Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints </td><td> Positive clinical effects  </td></tr><tr><td> <em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3) </td><td> None </td><td> Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints </td><td> Positive clinical effects  </td></tr><tr><td> <em>CYP2C19</em> UM (*17/*17) </td><td>  Helicobacter pylori eradication: increase dose by 400%. Be extra alert to insufficient response <br/>Other: be extra alert to insufficient response. Consider dose increase by 400% </td><td> Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints </td><td> Clinical effect (not statistically significant difference); Kinetic effect (not statistically significant difference) </td></tr></table><ul><li>#See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"moderate\" quality.</li></ul>"
}